IFW

## NATHE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bernd MISSELWITZ et al.

Serial No.: 10/616,511 Group Art Unit: 1616

Filed: 10 July 2003 Examiner: Unknown

For: USE OF PERFLUOROALKYL-CONTAINING METAL COMPLEXES AS CONTRAST MEDIA IN MR-IMAGING FOR VISUALIZATION OF INTRAVASCULAR THROMBI

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

XI	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:					
			three months of the filing date of a national application other than a CPA § 1.53(d);			
			three months of the actual filing date of the national phase of a PCT ation; OR			
	$\boxtimes$	before RCE).	e the mailing of a first substantive office action (including after filing of an			
			.R. § 1.97(c), this information disclosure statement is filed after the periods 7 C.F.R. § 1.97(b), but before the mailing date of:			
			a final rejection under 37 C.F.R. 1.113;			
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			
			a notice of allowance under 37 C.F.R. § 1.311; and			

		is acco	empanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
Statem	ients Un	ider 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
٠			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited I	Material	<u>ls</u>	
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$		s of materials listed but not attached were cited in an international search dated 19 May 2004.

		Copies of the materials listed are attached (except for the foregoing).
Non-E	English I	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	$\boxtimes$	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the</li> </ul>
		invention  E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date  D = cited in the application  L = cited for another reason  & = publication of member of same patent family
	$\boxtimes$	Translation of other relevant information on foreign search report
		In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
<u>Other</u>	Informa	ation
<u>Paym</u>	ent of Fe	ees Due (If Any):
	A chec	ck for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

 $\boxtimes$ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1911

Date: 8 July 2004

AJZ:at

K:\Sch\1911\Information Disclosure Statement.doc

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Please type a plus sign (+) ins

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known					
Application Number	10/616,511				
Filing Date	10 July 2003				
First Named Inventor	Bernd MISSELWITZ et al.				
Group Art Unit	1616				
Examiner Name	Unknown				
Attorney Docket Number	SCH-1911				

		U.S. Patent Document				
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY	
	1	6,019,959		Wolfgang EBERT et al.	02-01-2000	
	2	20030072713		Johannes PLATZEK et al.	04-17-2003	
	3	6743412		Thomas D. Harris	06-01-2004	
	4	6641797		Johannes PLATZEK et al.	11-04-2003	
	5	6468502		Johannes PLATZEK et al.	10-22-2002	
	6	6461587		Johannes PLATZEK et al.	10-08-2002	
	7	6676928		Johannes PLATZEK et al.	01-13-2004	
	8	5571498		William P. CACHERIS et al.	11-05-1996	
	9	6565828	•	Shuang LIU	05-20-2003	

				FOREIG	N PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Foreign Patent Docu Number <sup>4</sup>	ment Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	10	wo	0213874		Schering AG	02-21-2002		2
	11	wo	0108712		Randall B. LAUFFER et al	02-08-2001		
	12	wo	9816256		Schering AG	04-23-1998		3
	13	EP	1088558		Schering AG	04-04-2001		4
	14	wo	9726017		Schering AG	07-24-1997		5
	15	wo	9901161		Schering AG	01-14-1999		4
	16	wo	0056723		Schering AG	09-28-2000		6
	17	wo	0214309		Schering AG	02-21-2002		4
	18	wo	0213875	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Schering AG	02-21-2002	1/1-1944	7
	19	wo	9533494	,	Hemagen PFC	12-14-1995	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	8
	20	wo	0177102		Du Pont Pharm Co	10-18-2001		9
148-5	1							

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

PTO/SB/08A (08-00)

Please type a plus sign (+) inside

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/616,511 **INFORMATION DISCLOSURE** Filing Date 10 July 2003 STATEMENT BY APPLICANT Bernd MISSELWITZ et al. First Named Inventor Group Art Unit 1616 (use as many sheets as necessary) **Examiner Name** Unknown Sheet of Attorney Docket Number SCH-1911

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
	21	Yu Xin et al., "High-resolution MRI characterization of human thrombus using a novel fibrintargeted paramagnetic nanoparticle contrast agent," Magnetic Resonance in Medicine, December 2000, pages 867-872, vol. 44, no. 6, XP001155744, ISSN: 0740-3194, the entire document.					
<del>-</del>							

			<del></del>	
Examiner	·	Date		· ·
Signature		Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.